MCID: VRR004
MIFTS: 44

Verrucous Carcinoma

Categories: Cancer diseases, Oral diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Verrucous Carcinoma

MalaCards integrated aliases for Verrucous Carcinoma:

Name: Verrucous Carcinoma 11 14 16 75
Verrucous Squamous Cell Carcinoma 11
Verrucous Squamous Carcinoma 11
Carcinoma, Verrucous 43
Carcinoma Verrucous 53
Warty Carcinoma 11

Classifications:



External Ids:

Disease Ontology 11 DOID:3737
MeSH 43 D018289
NCIt 49 C3781
SNOMED-CT 68 89906000
UMLS 71 C0206706

Summaries for Verrucous Carcinoma

Disease Ontology: 11 A squamous cell carcinoma that is a diffuse, papillary, non metastasizing, well differentiated, malignant neoplasm of epidermis or oral epithelium.

MalaCards based summary: Verrucous Carcinoma, also known as verrucous squamous cell carcinoma, is related to esophagus verrucous carcinoma and anogenital venereal wart. An important gene associated with Verrucous Carcinoma is MSN (Moesin), and among its related pathways/superpathways are Endometrial cancer and Malignant pleural mesothelioma. The drugs Docetaxel and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include endothelial, lung and cervix, and related phenotypes are neoplasm and digestive/alimentary

Wikipedia: 75 Verrucous carcinoma (VC) is an uncommon variant of squamous cell carcinoma. This form of cancer is often... more...

Related Diseases for Verrucous Carcinoma

Diseases related to Verrucous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 520)
# Related Disease Score Top Affiliating Genes
1 esophagus verrucous carcinoma 31.6 TP53 PIK3CA EGFR CDKN2A CDH1
2 anogenital venereal wart 31.1 TP53 GP5 CDKN2A
3 suppressor of tumorigenicity 3 30.4 TP53 CDKN2A
4 squamous cell papilloma 30.3 TP53 GP5 CDKN2A
5 keratoacanthoma 30.3 TP53 PIK3CA KRT14 EGFR CDH1
6 inverted papilloma 30.1 TP53 KRT5 CDKN2A
7 muir-torre syndrome 30.1 TP53 KRT5 CDKN2A
8 penile benign neoplasm 30.1 TP53 PIK3CA PDPN GP5 CDKN2A
9 phimosis 30.1 TP53 GP5 CDKN2A
10 papilloma 30.1 TP53 KRT5 KRT14 EGFR CDKN2A CDH1
11 vulva cancer 30.0 TP53 PIK3CA GP5 EGFR CDKN2A
12 squamous cell carcinoma 29.9 TP53 PIK3CA PDPN KRT14 EGFR CDKN2A
13 oral submucous fibrosis 29.9 TP53 EGFR CDH1
14 laryngeal benign neoplasm 29.9 TP53 PIK3CA PDPN EGFR CDKN2A
15 endometrial squamous cell carcinoma 29.9 TP53 KRT5 CDKN2A
16 myoepithelial carcinoma 29.9 KRT5 KRT14
17 endometrial adenocarcinoma 29.9 TP53 EGFR CDKN2A
18 benign mesothelioma 29.8 PDPN KRT5 CDKN2A
19 epithelial-myoepithelial carcinoma 29.8 KRT5 KRT14
20 keratosis, seborrheic 29.8 TP53 PIK3CA KRT5 CDKN2A
21 lip and oral cavity cancer 29.8 TP53 PIK3CA EGFR CDKN2A CDH1
22 skin papilloma 29.8 TP53 KRT14 EGFR
23 epidermolysis bullosa 29.7 TP53 KRT5 KRT14
24 laryngeal squamous cell carcinoma 29.7 TP53 EGFR CDKN2A CDH1
25 vaginal cancer 29.7 TP53 GP5 EGFR CDKN2A
26 rectum adenocarcinoma 29.7 TP53 PIK3CA EGFR
27 peritoneal mesothelioma 29.7 TP53 PDPN KRT5 CDKN2A
28 actinic keratosis 29.6 TP53 KRT14 EGFR CDKN2A
29 vulva squamous cell carcinoma 29.6 TP53 PIK3CA GP5 EGFR CDKN2A
30 anus cancer 29.6 TP53 PIK3CA GP5 EGFR CDKN2A
31 anal squamous cell carcinoma 29.6 TP53 PIK3CA EGFR CDKN2A
32 endocervical carcinoma 29.6 TP53 PIK3CA EGFR CDKN2A
33 keratosis 29.5 TP53 PIK3CA KRT5 KRT14 EGFR CDKN2A
34 serous cystadenocarcinoma 29.5 TP53 PIK3CA CDKN2A CDH1
35 cervical cancer 29.4 TP53 PIK3CA MIR125A KRT14 CDKN2A
36 human papillomavirus infectious disease 29.4 TP53 PIK3CA MIR125A GP5 EGFR CDKN2A
37 skin carcinoma 29.4 TP53 KRT5 KRT14 EGFR CDKN2A CDH1
38 penile cancer 29.3 TP53 PIK3CA PDPN GP5 EGFR CDKN2A
39 skin squamous cell carcinoma 29.3 TP53 KRT5 KRT14 EGFR CDKN2A CDH1
40 squamous cell carcinoma, head and neck 29.2 TP53 PIK3CA MIR19A MIR195 MIR125A EGFR
41 colon adenocarcinoma 29.1 TP53 PIK3CA EGFR CDH1
42 head and neck cancer 29.1 TP53 PIK3CA MIR195 MIR125A EGFR CDKN2A
43 esophageal cancer 29.0 TP53 PIK3CA PDPN MIR125A KRT14 EGFR
44 basal cell carcinoma 29.0 TP53 KRT5 KRT14 EGFR CDKN2A CDH1
45 cervix carcinoma 28.9 TP53 PIK3CA GP5 EGFR CDKN2A CDH1
46 renal cell carcinoma, nonpapillary 28.3 TP53 PIK3CA PDPN MIR19A MIR195 MIR125A
47 meningioma, familial 28.2 TP53 PIK3CA PDPN MSN MIR195 EGFR
48 oropharynx cancer 28.2 TP53 PIK3CA KRT5 KRT14 GP5 EGFR
49 skin disease 27.9 TP53 PIK3CA MIR125A KRT5 KRT14 EGFR
50 larynx verrucous carcinoma 11.5

Graphical network of the top 20 diseases related to Verrucous Carcinoma:



Diseases related to Verrucous Carcinoma

Symptoms & Phenotypes for Verrucous Carcinoma

MGI Mouse Phenotypes related to Verrucous Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.63 CDH1 CDKN2A EGFR KRT14 PIK3CA TP53
2 digestive/alimentary MP:0005381 9.56 CDH1 CDKN2A EGFR KRT14 KRT5 PDPN
3 immune system MP:0005387 9.36 CD68 CDH1 CDKN2A EGFR KRT14 KRT5

Drugs & Therapeutics for Verrucous Carcinoma

Drugs for Verrucous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
2
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
3
Fluorouracil Approved Phase 3 51-21-8 3385
4 Angiogenesis Inhibitors Phase 3
5 Mitogens Phase 3
6 Antimetabolites Phase 3
7 Endothelial Growth Factors Phase 3
8 Immunoglobulin G Phase 3
9
Acetylcysteine Approved, Investigational Phase 2 616-91-1 581 12035
10 Raspberry Approved Phase 1, Phase 2
11
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
12
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
13
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908
14
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
15
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
16
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
17
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
18
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
19
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
20
Trioxsalen Approved Phase 2 3902-71-4 5585
21
Saracatinib Investigational Phase 2 379231-04-6 10302451
22
Cediranib Investigational Phase 2 288383-20-0 9933475
23
Maleic acid Experimental, Investigational Phase 2 110-16-7, 110-17-8 444266 444972
24
MK-1775 Investigational Phase 2 955365-80-7 24856436
25
Dihematoporphyrin ether Investigational Phase 2 97067-70-4
26
Diethyl ether Experimental Phase 2 60-29-7 3283
27 Antiviral Agents Phase 2
28 Anti-Infective Agents Phase 2
29 Expectorants Phase 2
30 Antidotes Phase 2
31 N-monoacetylcystine Phase 2
32 Respiratory System Agents Phase 2
33 Antioxidants Phase 2
34 Protective Agents Phase 2
35 Soy Bean Phase 2
36 Lactams Phase 2
37 Epothilones Phase 2
38 Epothilone B Phase 2 4456137
39 Anti-Bacterial Agents Phase 2
40 Antifungal Agents Phase 2
41 Antibiotics, Antitubercular Phase 2
42 topoisomerase I inhibitors Phase 2
43 Proteasome Inhibitors Phase 2
44 Photosensitizing Agents Phase 2
45 Dermatologic Agents Phase 2
46 Hematoporphyrin Derivative Phase 2
47
Lenograstim Approved, Investigational Phase 1 135968-09-1
48
Lenalidomide Approved Phase 1 191732-72-6 216326
49
Hydroxyurea Approved Phase 1 127-07-1 3657
50
Carboplatin Approved Phase 1 41575-94-4 10339178 38904

Interventional clinical trials:

(show top 50) (show all 57)
# Name Status NCT ID Phase Drugs
1 A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
2 A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies Completed NCT02123511 Phase 2 acetylcysteine
3 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention
4 A Phase II Trial of Preoperative Soy Isoflavone Supplementation and Molecular Markers in the Prevention of Head and Neck Squamous Carcinoma Completed NCT02007200 Phase 2 Soy Isoflavones
5 A Phase II Study of AZD0530 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Completed NCT00513435 Phase 2 saracatinib
6 A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma Completed NCT00507767 Phase 2 dasatinib
7 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
8 A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck Completed NCT00114283 Phase 2 lapatinib ditosylate
9 Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
10 A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
11 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab in Patients With Refractory, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00939627 Phase 2 sorafenib tosylate
12 A T1 Translational Multicenter Randomized Phase II Study of Temsirolimus Versus Cetuximab Plus Temsirolimus in Patients With Recurrent / Metastatic Head and Neck Cancer, Who Failed Prior EGFR Based Therapy Completed NCT01256385 Phase 2 Temsirolimus
13 A Biomarker Driven Pilot Study of the Pan-class I PI3K Inhibitor NVP-BKM120 in Combination With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer Completed NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
14 Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (Velcade TM) in Combination With Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
15 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
16 Phase II Trial Of Induction Chemotherapy Followed By Attenuated Chemoradiotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma Associated With Human Papillomavirus (HPV) Completed NCT02048020 Phase 2 paclitaxel;carboplatin
17 Phase II Clinical Trial of AZD2171 Monotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Patients Completed NCT00458978 Phase 2 Cediranib Maleate
18 A Phase 2 Study of SB-715992 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00095628 Phase 2 ispinesib
19 A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck Completed NCT01044433 Phase 2 lapatinib ditosylate;capecitabine
20 Phase II Trial of Carboplatin/Paclitaxel and Cetuximab, Followed by Carboplatin/Paclitaxel/Cetuximab and Erlotinib, With Correlative Studies in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
21 Efficacy and Safety of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal. Phase II Clinical Trial Completed NCT03584308 Phase 2
22 Randomized Placebo- Controlled Pilot Study of ZD6474 as a Chemopreventive Agent for Premalignant Lesions of the Head and Neck Completed NCT01414426 Phase 2 vandetanib
23 Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing Recruiting NCT02734537 Phase 2 Cisplatin
24 A Randomized Phase II Trial of Cisplatin With or Without Wee1 Kinase Inhibitor AZD1775 (MK-1775) for First-line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (RM-SCCHN) Terminated NCT02196168 Phase 2 Cisplatin;WEE1 Inhibitor AZD1775
25 A Phase II Study of Erlotinib and Radiation Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck Terminated NCT01192815 Phase 2 erlotinib hydrochloride
26 Interstitial Photodynamic Therapy During Standard Chemotherapy for Palliation of Patients With Head and Neck Squamous Cell Carcinoma - Phase II Terminated NCT02068157 Phase 2 Photodynamic Therapy;Porfimer Sodium
27 A Phase 2 Placebo Controlled Randomized Study of the Effect of SAMITAL on Severity and Duration of Mucositis Induced by Chemoradiation for Head and Neck Cancer (HNC) Withdrawn NCT01674374 Phase 2 Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules
28 A Randomized Multicenter Phase II Study Using HPPH With PDT Versus Standard of Care Surgery for Patients With T1/T2 Squamous Cell Carcinoma of the Oral Cavity Withdrawn NCT02119728 Phase 2 HPPH
29 Phase I Clinical Trial of VTX-2337, a Small Molecule Toll-Like Receptor 8 (TLR8) Agonist in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN) Completed NCT01334177 Phase 1 TLR8 agonist VTX-2337
30 A Phase I/II Clinical Trial of Sorafenib in Combination With Cisplatin and Docetaxel in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT02035527 Phase 1 sorafenib tosylate;cisplatin;docetaxel
31 A Phase I Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, OSI-774, in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck Completed NCT00049283 Phase 1 erlotinib hydrochloride;docetaxel
32 A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
33 A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vascular Endothelial Growth Factor) In Addition To Flourouracil And Hydroxyurea As Initial Chemotherapy With Concomitant Radiotherapy (B-FHX) For Poor Prognosis Head And Neck Cancer Completed NCT00023959 Phase 1 hydroxyurea;fluorouracil
34 Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC #707545) in Patients With Solid Tumors. Completed NCT00089362 Phase 1 alvespimycin hydrochloride
35 Enhancement of Cetuximab-Induced Antibody-Dependent Cellular Cytotoxicity (ADCC) With Lenalidomide in Advanced Solid Tumors: A Phase I/IB Study Completed NCT01254617 Phase 1 Lenalidomide
36 A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
37 Phase I Study of OSI-774 (NSC 718781) for Solid Tumors in Patients With Hepatic or Renal Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
38 A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
39 A Phase I Evaluation of Cetuximab and RAD001 in Patients With Solid Tumors Completed NCT01637194 Phase 1 everolimus
40 Nab-Paclitaxel-based Re-induction Chemotherapy Followed by Response-stratified Chemoradiotherapy in Patients With Previously Treated Squamous Cell Carcinoma of the Head and Neck. Active, not recruiting NCT01847326 Phase 1 carboplatin;paclitaxel albumin-stabilized nanoparticle formulation;fluorouracil;hydroxyurea
41 A Phase Ib Immunomodulatory Study of Single Agent Talactoferrin in Patients With Select Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) and Squamous Head and Neck Cancer (HNSCC) Terminated NCT01528137 Phase 1
42 A Phase I Trial of Concurrent Chemoradiation/Chemoreirradiation With Cetuximab (ERBITUX®), Sunitinib, and Accelerated Radiation in Patients With Locally Advanced/High-risk/Recurrent Poor Prognosis Head and Neck Cancer Terminated NCT00906360 Phase 1 sunitinib malate
43 A Phase 1 Study of Paclitaxel and Carboplatin in Solid Tumors (With Focus on Upper Aerodigestive Cancers) in Persons With HIV Infection Terminated NCT01249443 Phase 1 vorinostat;carboplatin;paclitaxel
44 A Phase I Dose Escalation Trial: Concurrent Intensity-Modulated Radiotherapy (IMRT) and Chemotherapy With Molecular Image-Guided Adaptive Radiation Therapy (IGART) for Advanced Head and Neck Squamous Cell Carcinomas (HNSCC) Terminated NCT01283178 Phase 1 cisplatin
45 A Phase I Study of CBLB502 in the Treatment of Patients With Poor Prognosis Advanced Squamous Cell Carcinomas of the Head and Neck Receiving Chemoradiotherapy Withdrawn NCT01728480 Phase 1 entolimod;cisplatin
46 A Phase I Dose Escalation Study of the mTOR Inhibitor Everolimus (RAD001) and Erlotinib Concurrently With Radiation Therapy in the Re-Irradiation Setting for Head and Neck Cancer Withdrawn NCT01332279 Phase 1 everolimus;erlotinib hydrochloride
47 L-lysine in the Treatment of Oral Mucositis in Head and Neck Cancer Patients- A Pilot Study Completed NCT01155609
48 Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger) Completed NCT00068497 gefitinib
49 Pilot Long-Term Oral Dose of Freeze-Dried Black Raspberries in Post-Surgical Appalachian Oral Cancer Completed NCT01504932
50 The Role of Direct Visual Fluorescence in Oral Examination Completed NCT01816841

Search NIH Clinical Center for Verrucous Carcinoma

Cochrane evidence based reviews: carcinoma, verrucous

Genetic Tests for Verrucous Carcinoma

Anatomical Context for Verrucous Carcinoma

Organs/tissues related to Verrucous Carcinoma:

MalaCards : Endothelial, Lung, Cervix, Breast, Lymph Node, Liver, Brain

Publications for Verrucous Carcinoma

Articles related to Verrucous Carcinoma:

(show top 50) (show all 1365)
# Title Authors PMID Year
1
Shifts in cellular localization of moesin in normal oral epithelium, oral epithelial dysplasia, verrucous carcinoma and oral squamous cell carcinoma. 53 62
12787041 2003
2
Expression of moesin and its associated molecule CD44 in epithelial skin tumors. 53 62
9696288 1998
3
Squamous Cell Carcinoma Arising from Perianal Buschke-Lowenstein Tumor (Giant Condyloma Acuminatum): Comprehensive Literature Review. 62
34694593 2022
4
Verrucous carcinoma within a segment of esophageal intramural pseudodiverticulosis. 62
36442724 2022
5
A case of verrucous carcinoma arising from a burn scar on the scalp of an HIV-positive patient. 62
36416661 2022
6
Retrospective evaluation of the oral brush biopsy in daily dental routine - an effective way of early cancer detection. 62
35881238 2022
7
Postoperative Radiation Therapy in Oral Cavity Verrucous Carcinoma. 62
34989407 2022
8
Outcome of Treatment in Verrucous Carcinoma of Oral Cavity: A Tertiary Rural Hospital Experience. 62
36452610 2022
9
HPV-independent, p53-wild-type vulvar intraepithelial neoplasia: a review of nomenclature and the journey to characterize verruciform and acanthotic precursor lesions of the vulva. 62
35437330 2022
10
Verrucous carcinoma of the vulva: Patterns of care and treatment outcomes. 62
35075817 2022
11
Treatment Pattern and Outcomes in Verrucous Carcinoma of Oral Cavity: A Single Institutional Retrospective Analysis from a Tertiary Cancer Center and Review of Literature. 62
36452609 2022
12
Pseudoepitheliomatous keratotic and micaceous balanitis: a series of eight cases. 62
35695159 2022
13
SOD3 Expression in Tumor Stroma Provides the Tumor Vessel Maturity in Oral Squamous Cell Carcinoma. 62
36359248 2022
14
WHO 2022 classification of penile and scrotal cancers: updates and evolution. 62
36221864 2022
15
Mohs micrographic surgery for verrucous carcinoma: a review of the literature. 62
36112206 2022
16
Cervical verrucous cancer misdiagnosed with verrucous hyperplasia: A case report. 62
36051273 2022
17
Proliferative verrucous leukoplakia: a clinicopathological comparative study. 62
35065850 2022
18
"In response to "Oral verrucous carcinoma manifesting as proliferative verrucous leukoplakia". 62
35653816 2022
19
Definitive Radiotherapy versus Surgery for the Treatment of Verrucous Carcinoma of the Larynx: A National Cancer Database Study. 62
35846806 2022
20
Verrucous carcinoma of the esophagus with complete response after chemoradiotherapy. 62
35781764 2022
21
Surgical treatment of verrucous carcinoma: a review. 62
33849379 2022
22
Autoreconstruction of the tongue in case of extensive verrucous carcinoma. 62
36051808 2022
23
A Case of Verrucous Carcinoma Treated by Combination of Radiotherapy and Mohs' Chemosurgery. 62
36158855 2022
24
Association of HPV and EBV in Oral Verrucous Squamous Cell Carcinoma and Oral Verrucous Hyperplasia. 62
34856629 2022
25
[Expression of TNFAIP6 in oral verrucous carcinoma and oral squamous cell carcinoma and its relationship with clinicopathology]. 62
36110074 2022
26
Caveats in the diagnosis of suspected non-endemic verrucous carcinoma in the urinary bladder. 62
35347834 2022
27
Verrucous Carcinoma of the Foot: A Retrospective Study of 19 Cases and Analysis of Prognostic Factors Influencing Recurrence. 62
35659148 2022
28
Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Tumours of the Oral Cavity and Mobile Tongue. 62
35312982 2022
29
Role of cancer-associated fibroblasts in oral squamous cell carcinomas, surgical margins, and verrucous carcinomas: An immunohistochemical study. 62
35261929 2022
30
Cutaneous verrucous carcinoma: A clinicopathological study of 21 cases with long-term clinical follow-up. 62
36313691 2022
31
Oral verrucous carcinoma arising from pemphigus vulgaris: A rare coincidence. 62
34518111 2022
32
Immunohistochemical expression and evaluation of cyclin D1 and minichromosome maintenance 2 in oral squamous cell carcinoma and verrucous carcinoma. 62
35571317 2022
33
Perspective of nuclear fractal dimension in diagnosis and prognosis of oral squamous cell carcinoma. 62
35571291 2022
34
Oral carcinoma cuniculatum: an unacquainted entity with diagnostic challenges-a case report. 62
35037108 2022
35
Laryngeal malignancies - epidemiological data and particularities of the cases diagnosed in Western Romania (October 2016-July 2020). 62
36074679 2022
36
Warty carcinoma of the uterine cervix: a virus-induced disease? 62
36160345 2022
37
Efficacy of diode lasers in oral verrucous hyperplasia: A case series. 62
35911798 2022
38
Squamous Cell Carcinoma of the Foot Occurring in a Wart. 62
35016565 2022
39
Radiation vs surgery for early-stage laryngeal verrucous carcinoma: A population-based propensity score matched-study. 62
36315501 2022
40
Verrucous carcinoma of buccal mucosa in female - a rare case scenario. 62
35519163 2022
41
Verrucous hyperplasia and verrucous carcinoma in head and neck: use and benefit of methotrexate. 62
32279645 2021
42
Correction to: Complex microsurgical perineal reconstruction after resection of a giant verrucous carcinoma associated with anal fistulas in Crohn's disease-a unique case report. 62
34716770 2021
43
[Mass Screening of Oral Cancer in Eastern Shimane Prefecture during 2015-2019]. 62
35045504 2021
44
Verrucous carcinoma arising from actinic keratosis: a case report. 62
34974690 2021
45
Angiokeratoma Circumscriptum Naeviforme Presenting as a Dark Warty Plaque on the Leg. 62
34990348 2021
46
Buschke-Lowenstein Tumors: A Review and Proposed Classification System. 62
33833150 2021
47
Radial forearm free flap in a patient with an unusual radial artery variation: a case report. 62
34818712 2021
48
Flexible endoscopic approach to verrucous carcinoma of the larynx. 62
34473404 2021
49
Rare combination of verrucous carcinoma and syringocystadenoma papilliferum in anterior perineal sinus: recognizing the absence of normality. 62
33792154 2021
50
Verrucous carcinoma of the oesophagus is a genetically distinct subtype of oesophageal squamous cell carcinoma. 62
33960520 2021

Variations for Verrucous Carcinoma

Expression for Verrucous Carcinoma

Search GEO for disease gene expression data for Verrucous Carcinoma.

Pathways for Verrucous Carcinoma

Pathways related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.45 CDH1 CDKN2A EGFR PIK3CA TP53
2 12.41 TP53 PIK3CA EGFR CDKN2A CDH1
3 12.33 PDPN MSN KRT5 CDH1
4
Show member pathways
12.26 TP53 PIK3CA EGFR CDH1
5
Show member pathways
11.82 TP53 PIK3CA EGFR
6 11.61 PIK3CA EGFR CDKN2A CDH1
7 11.56 TP53 KRT5 KRT14
8 11.46 TP53 MIR19A MIR195
9 11.22 KRT5 KRT14 CDKN2A
10 11.12 TP53 PIK3CA EGFR CDKN2A
11 11.07 PIK3CA EGFR CDH1
12 10.78 TP53 CDKN2A
13 10.59 PIK3CA EGFR CDH1
14 10.53 TP53 EGFR CDKN2A CDH1
15 10.52 PIK3CA EGFR
16 10.51 TP53 CDH1

GO Terms for Verrucous Carcinoma

Biological processes related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of interleukin-6 production GO:0032715 9.54 MIR19A MIR195 MIR125A
2 negative regulation of oxidative stress-induced cell death GO:1903202 9.32 MIR19A MIR195
3 positive regulation of miRNA maturation GO:1903800 9.26 TP53 EGFR
4 negative regulation of receptor signaling pathway via STAT GO:1904893 9.16 MIR125B1 MIR125A
5 negative regulation of gene expression GO:0010629 9.1 TP53 PIK3CA MIR19A MIR125B1 MIR125A
6 negative regulation of interleukin-6-mediated signaling pathway GO:0070104 8.96 MIR125B1 MIR125A

Molecular functions related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA base-pairing translational repressor activity GO:1903231 9.26 MIR19A MIR195 MIR125B1 MIR125A
2 mRNA 3'-UTR binding GO:0003730 9.1 TP53 MIR19A MIR195 MIR125B1 MIR125A

Sources for Verrucous Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....